ampiroxicam: prodrug of piroxicam; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ampiroxicam : A benzothiazine that is the 1-[(ethoxycarbonyl)oxy]ethyl ether of piroxicam. A prodrug for piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 2176 |
| CHEMBL ID | 1566249 |
| CHEBI ID | 31210 |
| SCHEMBL ID | 49363 |
| SCHEMBL ID | 21357883 |
| MeSH ID | M0181118 |
| Synonym |
|---|
| AC-18891 |
| HMS3394J03 |
| AB00698363-05 |
| cp-65703 |
| nacyl |
| flucam |
| ampiroxicam |
| ampiroxicamum [latin] |
| brn 5184713 |
| carbonic acid, ethyl 1-((2-methyl-3-((2-pyridinylamino)carbonyl)-2h-1,2-benzothiazin-4-yl)oxy)ethyl ester, s,s-dioxide |
| (+-)-4-(1-hydroxyethoxy)-2-methyl-n-2-pyridyl-2h-1,2-benzothiazine-3-carboxamide ethyl carbonate (ester), 1,1-dioxide |
| cp 65703 |
| MLS001424306 |
| smr000469285 |
| flucam (tn) |
| D01397 |
| ampiroxicam (jp17/inn) |
| 99464-64-9 |
| NCGC00164605-01 |
| HMS2090I13 |
| HMS2052J03 |
| methyl 3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]oct-3-ene-4-carboxylate |
| ethyl 1-{[2-methyl-1,1-dioxido-3-(pyridin-2-ylcarbamoyl)-2h-1,2-benzothiazin-4-yl]oxy}ethyl carbonate |
| dtxsid6046474 , |
| cas-99464-64-9 |
| tox21_112227 |
| dtxcid4026474 |
| pharmakon1600-01504830 |
| nsc759807 |
| nsc-759807 |
| HMS2232L11 |
| S4011 |
| CCG-101155 |
| 0pv32jzb1j , |
| nsc 759807 |
| ampiroxicam [inn:ban:jan] |
| ampiroxicamum |
| unii-0pv32jzb1j |
| FT-0602844 |
| AKOS015900478 |
| (+/-)-4-(1-hydroxyethoxy)-2-methyl-n-2-pyridyl-2h-1,2-benzothiazine-3-carboxamide ethyl carbonate (ester), 1,1-dioxide |
| ampiroxicam [jan] |
| ampiroxicam [inn] |
| ampiroxicam [mi] |
| ampiroxicam [who-dd] |
| ampiroxicam [mart.] |
| chebi:31210 , |
| CHEMBL1566249 |
| cp-65,703 |
| carbonic acid ethyl 1-({2-methyl-3-[(2-pyridinylamino)carbonyl]-2h-1,2-benzothiazin-4-yl}oxy)ethyl ester s,s-dioxide |
| HMS3372K07 |
| CCG-213956 |
| HY-17484 |
| SCHEMBL49363 |
| NC00405 |
| tox21_112227_1 |
| NCGC00164605-02 |
| AC-32693 |
| AB00698363_06 |
| AB00698363_07 |
| ethyl 1-[[2-methyl-1,1-dioxo-3-(pyridin-2-ylcarbamoyl)-1lambda6,2-benzothiazin-4-yl]oxy]ethyl carbonate |
| sr-01000763537 |
| SR-01000763537-3 |
| ethyl 1-([2-methyl-1,1-dioxido-3-[(2-pyridinylamino)carbonyl]-2h-1,2-benzothiazin-4-yl]oxy)ethyl carbonate |
| ethyl (1-((2-methyl-1,1-dioxido-3-(pyridin-2-ylcarbamoyl)-2h-benzo[e][1,2]thiazin-4-yl)oxy)ethyl) carbonate |
| HMS3652M15 |
| ampiroxicam, >=98% (hplc) |
| HMS3715N12 |
| SW219542-1 |
| Q3614672 |
| SCHEMBL21357883 |
| BCP13545 |
| BRD-A39172021-001-06-1 |
| HMS3885A18 |
| C77384 |
| ethyl 1-[[2-methyl-1,1-dioxo-3-(pyridin-2-ylcarbamoyl)-1$l^{6,2-benzothiazin-4-yl]oxy]ethyl carbonate |
| AS-56304 |
| ampiroxicam- bio-x |
| BA164172 |
Ampiroxicam is a nonacidic ether carbonate prodrug of piroXicam.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Ampiroxicam is a nonacidic ether carbonate prodrug of piroxicam. " | ( Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam. Carty, TJ; Falkner, FC; Marfat, A; Moore, PF; Twomey, TM; Weissman, A, 1993) | 3.17 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Ampiroxicam, however, has similar in vivo potency to piroxicam in suppressing paw swelling in rat adjuvant arthritis." | ( Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam. Carty, TJ; Falkner, FC; Marfat, A; Moore, PF; Twomey, TM; Weissman, A, 1993) | 2.45 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The aim of the present study was to determine the effect of sulfaphenazole (SP) on the pharmacokinetics of ampiroxicam (AM) which is metabolized by cytochrome P-450 (CYP) 2C9, since SP is a potent inhibitor of CYP 2C9, and so a dramatic pharmacokinetic drug interaction between both drugs is assumed after dosing." | ( Pharmacokinetic drug interactions between ampiroxicam and sulfaphenazole in rats. Iwaki, M; Kobayashi, E; Ogiso, T; Sawada, A; Tanaka, H; Tanino, T; Uno, S, 1999) | 0.78 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Bioavailability studies show that conversion to piroxicam is about 100%, 90%, 70%, and 50% in these four species, respectively." | ( Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam. Carty, TJ; Falkner, FC; Marfat, A; Moore, PF; Twomey, TM; Weissman, A, 1993) | 1.73 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ampiroxicam itself is not observed in plasma after oral dosing to man, nor in the rat, dog, and monkey as reported here." | ( Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam. Carty, TJ; Falkner, FC; Marfat, A; Moore, PF; Twomey, TM; Weissman, A, 1993) | 2.64 |
| " When SP was preloaded orally at 2 h before the dosing of AM, and when AM and SP were orally coadministered for 7 d, the elimination of PX from plasma was slightly retarded and the area under the plasma concentration-time curve (AUC) was increased 77 and 53%, respectively, but not significantly, compared with those after AM alone." | ( Pharmacokinetic drug interactions between ampiroxicam and sulfaphenazole in rats. Iwaki, M; Kobayashi, E; Ogiso, T; Sawada, A; Tanaka, H; Tanino, T; Uno, S, 1999) | 0.57 |
| Role | Description |
|---|---|
| prodrug | A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. |
| analgesic | An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. |
| non-steroidal anti-inflammatory drug | An anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. |
| antirheumatic drug | A drug used to treat rheumatoid arthritis. |
| EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor | A compound or agent that combines with cyclooxygenases (EC 1.14.99.1) and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of icosanoids, prostaglandins, and thromboxanes. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| benzothiazine | |
| sulfonamide | An amide of a sulfonic acid RS(=O)2NR'2. |
| aminopyridine | Compounds containing a pyridine skeleton substituted by one or more amine groups. |
| monocarboxylic acid amide | A carboxamide derived from a monocarboxylic acid. |
| etabonate ester | |
| acetal | An organooxygen compound having the structure RR'C(OR'')(OR''') (R'', R''' =/= H). Mixed acetals have R'' and R''' groups which differ. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 3.1654 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| AR protein | Homo sapiens (human) | Potency | 15.3947 | 0.0002 | 21.2231 | 8,912.5098 | AID743040; AID743042; AID743054 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 6.6507 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692; AID720719 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 13.5228 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075 |
| G | Vesicular stomatitis virus | Potency | 38.9018 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 5.3080 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 4.9066 | 0.0056 | 12.3677 | 36.1254 | AID624032; AID624044 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 3.9811 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| Interferon beta | Homo sapiens (human) | Potency | 38.9018 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 38.9018 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 16.7855 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 3.1623 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 38.9018 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 3.3491 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
| Ataxin-2 | Homo sapiens (human) | Potency | 3.3491 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 38.9018 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (33.33) | 18.2507 |
| 2000's | 4 (14.81) | 29.6817 |
| 2010's | 8 (29.63) | 24.3611 |
| 2020's | 6 (22.22) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.23) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (11.11%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 5 (18.52%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 19 (70.37%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||